Morgan Stanley notes that Hims & Hers beat in Q4 and guided Q1 and calendar year 2025 revenue significantly above the Street consensus.

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

Hims & Hers (HIMS) stock dips as Morgan Stanley downgrades the telehealth firm citing its recent rally in share price. Read more here.

In a report released today, Korinne Wolfmeyer from Piper Sandler maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), ...

Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...

Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...